辅助赛诺巴酸按焦发作亚型的有效性:在一个跨国亚洲人口中进行的一项随机,双盲,安慰剂控制的多中心研究
Xintong Wu1, Ling Chen2, Eunyeong Choe3
1Department of Neurology, West China Hospital, Sichuan University, Chengdu, China.
Seizure
|October 16, 2025
概括
在亚洲成年人中,雪诺巴显著减少了焦点发作,在所有发作类型中都有剂量依赖的改善. 观察到很高的无发作率,特别是在焦点到双边强力-克隆性发作中.
科学领域:
- 神经学 神经学
- 临床药理学 临床药理学
背景情况:
- 焦点影响全球数百万人,不受控制的发作导致显著的发病率和死亡率.
- 亚洲人群往往对抗药物表现出独特的反应,需要进行特定的疗效评估.
研究的目的:
- 评估亚洲成年人患有不受控制的焦点的辅助赛诺巴酸的疗效.
- 评估塞诺巴马特在不同焦点发作亚型中的有效性:焦点知觉运动 (FAM),焦点知觉障碍 (FIA) 和焦点到双边强力-克隆性 (FBTC).
主要方法:
- 一项为期24周的随机,双盲,安慰剂对照研究 (NCT04557085) 涉及519名亚洲成年患者,患有不受控制的焦点.
- 患者接受了赛诺巴马特 (100,200或400毫克/天) 或安慰剂,剂量定位为18周,随后是6周的维持阶段.
- 在维持期间和12周治疗期间,分析了FAM,FIA和FBTC发作的发作频率减少和响应率.
主要成果:
- 在所有剂量和子类型中,辅助赛诺巴显示了数量上比安慰剂更大的发作频率降低.
- 在维持阶段,每天服用200和400毫克的塞诺巴剂可以使发作频率中位数减少76%-100%.
- 在FAM中,没收率高达52.4%,在FIA中达到57.5%,在FBTC中达到75.0%. 常见的不良事件包括头和昏昏欲睡.
结论:
- 在亚洲成年患有焦点患者中,cenobaamate有效地以剂量依赖的方式减少了焦点的亚型.
- 该药物显示出显著的疗效,特别是在发生焦点到双边强力克隆性的患者中,无发作率特别高.
- 这些发现凸显了巴作为一种辅助疗法的潜力,用于管理这个人群中各种焦点的呈现.
更多相关视频
相关概念视频
01:20Antiepileptic Drugs: Potassium Channel Activators
631
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
631
01:14Antiepileptic Drugs: Glutamate Antagonists
888
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
888
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
814
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
814
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
1.2K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.2K
01:30Electroconvulsive Therapy
864
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
864
01:17Antiepileptic Drugs: Calcium Channel Blockers
1.1K
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.1K